Souhaitez-vous accéder aux communiqués récents ?
Créez un compte lecteur dès aujourd’hui afin de suivre les secteurs et les entreprises qui vous intéressent, et configurer votre tableau de bord.
-
Wegovy Pill vs Wegovy Shot: Daily oral vs weekly injectable semaglutide differences following 2026 FDA approval. Ro.co access pathway examined.
-
Direct Meds reviews best GLP-1 weight loss shot prescription pathways for 2026 as oral semaglutide and injectable formats expand patient access.
-
MEDVi GLP-1 Investigation: What Consumer Data Shows About Compounded Telehealth Weight Loss Programs
Analysis examines MEDVi's compounded GLP-1 semaglutide telehealth model, FDA compounding framework, and prescription weight loss trends for 2026.
-
SynergyRx outlines how its telehealth platform connects patients with licensed providers for GLP-1 evaluation, pricing context, and pathways.
-
FDA approves oral Wegovy pill Dec 2025. Analysis compares FDA-approved injectable, oral, and compounded semaglutide access pathways for 2026.
-
MEDVi lists compounded GLP-1 injections at $179 first month, $299 refills as 100,000+ patients seek affordable semaglutide ahead of 2026 New Year.
-
BROOKLYN, June 19, 2025 (GLOBE NEWSWIRE) -- HealthRX, a digital health platform serving adults across the United States, has announced an expanded online experience designed to support weight...